text:
Home » Posts tagged 'ab segulah'
Tag Archives: ab segulah
Advanced Oncotherapy #AVO – Exclusive distribution agreement for China and other geographies & new equity investments for a total consideration of £37m
7th December 2017 / Leave a comment
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an exclusive distribution agreement with Yantai CIPU Medical Technology Co. Ltd. to market and sell Advanced Oncotherapy's LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. Under the agreement, Yantai CIPU will make a payment of £16.5 million to Advanced Oncotherapy.
At the same time, the Company has secured £20.9 million of equity investments to fund the continuing technical development of its first LIGHT system and its installation at the Harley Street Proton Therapy Centre.
Advanced Oncotherapy to raise a total £37.4 million of financing, of which £30.0 million from Yantai CIPU and £7.4 million from other investors;
Yantai CIPU to pay Advanced Oncotherapy £16.5 million to market and sell Advanced Oncotherapy's LIGHT systems across China, Macau, Taiwan, Hong-Kong and South Korea;
Yantai CIPU to subscribe for 45 million shares at 30p, raising £13.5 million equity finance;
Other investors to subscribe for 24.6 millionshares at 30p, raising £7.4 million. These other investors include members of the Board, as well as the members of the consortium formed by AB Segulah who are converting the loan made to the Company in July 2017 and interests of a total of £4.1 million;
The subscription price of 30p per share represents a premium of 2% to the volume-weighted average share price of one month prior to 1 December 2017.
Distribution Agreement with Yantai CIPU
Yantai CIPU and the Company have entered into a distribution agreement whereby Yantai CIPU has been appointed as the exclusive distributor in the People's Republic of China, Hong Kong, Macau, Taiwan and South Korea of the LIGHT system, the Company's proprietary proton accelerator. As part of the distribution agreement, Yantai CIPU has agreed to pay Advanced Oncotherapy £16.5 million. The receipt of funds is subject to approval from the Government of the People's Republic of China for the transfer of monies to the United Kingdom.
Having already identified eleven potential installation sites for the LIGHT system, Yantai CIPU and the Company have committed to a target of three installations over the first four years and the financing of ten further systems following the regulatory approval of the LIGHT system in China. Going forward, the Board remains confident that there will be a high demand for the product, particularly as precision medicine has been listed as one of the strategic industries to receive support in the People's Republic of China's 13th Five-Year Plan for economic and social development (2016-20).
As part of the distribution agreement, Advanced Oncotherapy will issue to Yantai CIPU 500,000 warrants to subscribe for Ordinary Shares pursuant to the terms of a warrant deed to be executed by the Company at the time of admission of the new Ordinary Shares as detailed below in respect of each binding purchase agreement for the sale of a LIGHT system up to a maximum of 11 purchase agreements. The Warrants are exercisable for five years after issuance at an exercise price equal to 130% of the one-month average share price prevailing on the date of the delivery of a LIGHT System.
About Yantai CIPU
Based in Yantai, China, Yantai CIPU invests in the health industry, including the field of high-end medical equipment companies, both in China and internationally. Yantai CIPU is ultimately owned by the Han family.
Equity Investment from Yantai CIPU
In addition, Advanced Oncotherapy has signed a subscription agreement with Yantai CIPU, whereby Yantai CIPU will subscribe for 45,000,000 ordinary shares of £0.25 each in the capital of Advanced Oncotherapy ("Ordinary Shares") at a price of 30p per Ordinary Share (the "Subscription Shares"), providing gross funds of £13,500,000. Shareholders should be aware that these funds are not currently in the UK and the receipt of these funds and of the funds under the Distribution Agreement is subject to approval from the Government of the People's Republic of China for the transfer of monies to the United Kingdom.
In addition, the Equity Investment by Yantai CIPU is subject to the approval of the Advanced Oncotherapy shareholders as set out below and to completion of customary due diligence in relation to a new substantial shareholder in an AIM quoted company.
It is expected that Mrs. Zhang RenHua and Mr. Chunlin Han, will join the Board of Advanced Oncotherapy following completion of the subscription by Yantai CIPU and completion of the requisite due diligence procedures for the appointment of directors to the board of an AIM quoted company. A further announcement regarding their appointment will be made in due course. The Board expects that the Company's strategy for the LIGHT system's commercial roll-out in Asia will benefit greatly from the Han family's extensive knowledge and experience in this area. Together, the Company and Yantai CIPU intend to explore opportunities to manufacture parts of the LIGHT system in the region.
Conditional upon completion of the subscription by Yantai CIPU, certain existing or new shareholders in the Company have also agreed to subscribe for, and/or convert outstanding loans into, new Ordinary Shares.
This includes the consortium formed by AB Segulah, a significant shareholder of the Company, AFMS Radgivning Och Invest AB, Peter Gyllenhammar AB, Mijesi AB and Emendum AB, who are converting the loan made to the Company in July 2017 and interests of a total of £4.1 million into 13,555,617 Ordinary Shares (the "Conversion").
Executive Directors Dr. Michael Sinclair, Pr. Stephen Myers, Nicolas Serandour, and Non-Executive Directors Henri Vanni, and Dr Nick Plowman have agreed to subscribe in total for 4,279,050 Ordinary Shares at a price of £0.30 per Ordinary Share, providing additional funds of £1,283,715.
The subscription by Yantai CIPU, the directors and other investors and the Conversion will be subject to shareholder approval for the authority to issue the relevant Ordinary Shares as set out in a Circular to be sent to shareholders shortly. Following completion of these transactions, the total number of shares in Advanced Oncotherapy will amount to 150,501,672. Yantai CIPU will hold 29.9% of the enlarged issued share capital of the Company.
The participations by Yantai CIPU, AB Segulah, other investors and certain directors in the transactions set out above and their resulting holdings in the enlarged share capital of the Company will be as follows:
Investment Number of newly subscribed shares Percentage of enlarged share capital held after completion of the transactions
Yantai CIPU £ 13,500,000 45,000,000 29.9%
Consortium led by AB Segulah (Loan Conversion) £ 4,066,685 13,555,617 12.6%
Dr Michael Sinclair, Executive Chairman £ 500,000 1,666,667 4.4%
Nicolas Serandour, CEO £ 500,000 1,666,667 1.2%
Prof Stephen Myers, Executive Chairman of ADAM £ 100,000 333,333 0.5%
Henri Vanni, NED £ 137,500 458,333 1.1%
Dr. Nick Plowman, NED £ 46,215 154,050 2.4%
Other investors £ 2,019,543 6,731,812 4.9%
Total £ 20,869,943 69,566,479
Lancea LLP advised the Company on the Subscription and Distribution agreements made by Yantai CIPU.
Status of loan facility by Metric Capital Partners
Advanced Oncotherapy and Metric Capital Partners have confirmed their intention to continue to work towards the provision of a £24 million loan facility. Terms and conditions are being updated to reflect the developments since the initial announcement of the agreement with Metric Capital Partners in May 2016.
Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy, said: "I am delighted that we have been able to conclude deals to provide shareholders not only with the security of longer-term financing, but which also introduce a new experienced strategic investor with strong distribution capacity and already established commercial interest in Asia, particularly in one of our key target markets, China.
"It is a little over a year now since I took on the role of Chief Executive Officer and I am pleased to note that as the calendar year draws to a close we have successfully integrated and tested the proton source, RFQ and SCDTL significantly de-risking the development process. We are also pleased with the progress of the Harley Street site with the next stage of sub-structural work well underway.
"This deal is consistent with our strategy to focus our resources on the technological development of the first LIGHT system and to establish partnerships with those businesses that have a strong track record of market access and a unique expertise in their own geographies. With our long-term financing arrangements now well engaged we can continue to focus on making our unique proton therapy technology available to patients around the world."
Advanced Oncotherapy Plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 20 3617 8728
Nicolas Serandour, CEO
Stockdale Securities (Nomad & Joint Broker)
Antonio Bossi / Ed Thomas Tel: +44 20 7601 6100
Stifel Nicolaus Europe (Joint Broker)
Jonathan Senior / Ben Maddison Tel: +44 20 7710 7600
Walbrook PR (Financial PR & IR) Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 541 893 / Mob: +44 7876 741 001
Lancea LLP (Advisors)
Pascal Isbell / Samuel Ogunsalu Tel +44 20 3301 8015 / +44 20 3301 8005
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Advanced Oncotherapy (AVO) – Interim results announcement
29th September 2017 / Leave a comment
Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment, announces its unaudited results for the six months ended 30 June 2017 and post-period events.
· Technological milestones reached with successful integration and testing of proton source, RFQ and SCDTL significantly de-risking development process
· Progress at the Harley Street site on-track with next stage of sub-structural work underway through Deconstruct
· Preparation of two production lines for LIGHT system commercial roll-out
· Additional financing from consortium led by longstanding shareholder AB Segulah, with long-term financing options under consideration
· Strengthening of scientific and operational expertise
· Shareholder funds of £32.01 million as at 30 June 2017, up from £22.63 million a year earlier; cash and cash equivalents of £235,437, with a post period end £3.90 million financing from AB Segulah consortium and corporation tax R&D refund of £3.05 million received
Nicolas Serandour, CEO of Advanced Oncotherapy, said: "Technological development of our LIGHT system continues to be on track and, through the successful integration and testing of three of the four key structures of LIGHT's accelerating system, we have significantly de-risked the development process and have overcome the greatest technical challenges that this system faces. We are now well positioned to accelerate the proton beam through additional SCDTL modules and, beyond that, to integrate the fourth key component, the CCLs. The Harley Street site also progresses well and our principal contractor Deconstruct remains on schedule.
"As our technological progress advances we find ourselves in a much stronger position as we assess financing options and we have been encouraged by positive feedback. We have been able to put financing agreements in place and we hope to provide an update to shareholders on longer-term financing options in due course.
"We will update shareholders regularly on our future progress and we remain on track to build a proton therapy system capable of treating superficial tumours by the end of Q3 2018."
Advanced Oncotherapy Plc
www.avoplc.com
Dr. Michael Sinclair, Executive Chairman
Antonio Bossi / David Coaten
Jonathan Senior / Ben Maddison
Walbrook PR (Financial PR & IR)
Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy
Mob: +44 7980 541 893 / Mob: +44 7876 741 001
Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator – LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.
EXECUTIVE CHAIRMAN'S STATEMENT
I am delighted to update shareholders with our report for the six months ended 30 June 2017 and to provide a review of the further significant progress being made in the technical development of our next generation proton therapy system, LIGHT.
We are very pleased with the considerable advances that have been made to date with the successful integration of three of the four key structures for LIGHT's accelerating system, a milestone which has greatly reduced the overall technical risk of this project. Progress at our flagship Harley Street site remains on track and additional funding agreements allow us to approach long-term financing options from a stronger base. We continue to be mindful of our future ability to meet a huge medical need with a successful commercial roll-out of the LIGHT system once development of our first system is completed and I will update on progress in this area below. We remain confident that demand for our next-generation proton therapy system will be strong and that additional commercial sales will be secured in due course.
Most importantly, we remain firmly on track to build a proton therapy system capable of treating superficial tumours by the end of Q3 2018, a critical milestone that once reached will mark a significant inflection point for delivering value to shareholders.
During the six months to 30 June 2017 and beyond we have made significant advancements in the technology development and manufacture of our first LIGHT system. As a reminder, our system has four key components that are integral to the successful completion of a system capable of patient treatment. The first unit is the proton source which then feeds the protons to the second component, the Radio Frequency Quadrupole ("RFQ"). As we announced in March 2017, we achieved a significant technological milestone by firing a proton beam through the integrated proton source and RFQ at the maximum design-anticipated energy of 5 MeV. The next stage is for the beam to pass through the low-speed accelerators, the Side Coupled Drift Tube Linacs ("SCDTLs"), before passing through the high-speed accelerators, the Coupled Cavity Linac ("CCL") modules, the fourth key structure.
Whilst all four structures had already been tested individually and the proton source successfully integrated with the RFQ and demonstrated to be functioning as expected, we were able to update shareholders earlier this month on completion of another key technological milestone: namely the successful integration and testing of three of the four key elements of the LIGHT system for the first time.
The integration of the first SCDTL with the RFQ and proton source, with acceleration of the proton beam through all integrated units marks a further de-risking of the technological development process, given that it is materially more challenging to accelerate protons at lower speeds.
Much of the linear accelerator technology has already been validated through the successful testing of the Linac Booster ("LIBO") prototype. LIBO is a "high speed" accelerator and most closely matches the design and operational requirements of the CCL modules, and so this, combined with the latest successful integration of the first three key LIGHT structures, should provide shareholders with confidence that the greatest technological challenges of this project have already been overcome.
During the period we also announced that the LIGHT system's unique ionisation chamber was received from our partner Pyramid Technical Consultants Inc. The ionisation chamber is a critical element of LIGHT's overall safety system, monitoring beam position, spot size and dosage, and will be part of the delivery system in the treatment rooms. In addition, the patient positioning subsystem, which includes the patient treatment chair and robotic arm which moves the chair and patient, had been completed and as other subsystems are completed, such as imaging and treatment management software, they will be integrated to form the whole Patient Positioning System ("PPS").
Harley Street update
Progress at 141/143 Harley Street continues apace and we are very pleased with the works already carried out by Deconstruct (UK) Limited ("Deconstruct") who were appointed and are being paid by The Howard de Walden Estate as principal contractor to the Harley Street construction project. Deconstruct are highly experienced in strategic demolition and in particular in the technical expertise needed to preserve the integrity and appearance of Grade 2 listed buildings, such as 141/143 Harley Street.
Deconstruct came on site in January to carry out preliminary assessment and have already completed the structural demolition and enabling work required in the first stages of this project. The next stage of sub-structural works is now underway with the secant piling, required to secure the retaining walls in the basement of the building, now well underway. A short video on the progress of the site can be seen on our website here: www.avoplc.com
The work at Harley Street for the creation of the Harley Street Proton Therapy Centre, the site of central London's first proton therapy centre, remains on schedule and we have every confidence that we are on-track for the site to be ready for installation by H1 2019 with first patient treatment expected by mid-2020.
Future plans for commercialisation
Whilst the technical development of our first LIGHT system and the Harley Street site is a key focus of the Company we must also be mindful of our ability to respond to the huge worldwide medical need for access to an affordable proton therapy technology that can be easily installed and safely operated in areas of high patient population density.
To this end we continue to work with our manufacturing partners to make the preparations necessary for the manufacture and building of our completed LIGHT systems through the construction of two production lines capable of producing eight machines per year. Whilst these production volumes are expected at the initial stage of roll-out, we are well positioned to further ramp-up production of our system. Because of the LIGHT system's modular nature, mass production capability, compactness and requirement for less shielding, we are in a good position to increase production to meet demand and also ensure lower manufacturing and installation lead times.
In terms of our existing pipeline for the LIGHT system, we continue to receive substantial interest in the technology. We remain in discussions for a second site in Birmingham. As well as this, we are looking at a number of sites in the USA and multiple other opportunities in Europe, Asia and the Middle East. We retain full distribution rights for the LIGHT proton therapy system in China and other countries in South East Asia and remain of the opinion that this will be an exciting and dynamic potential market for our technology and are confident that we will achieve commercial success here, having received strong indications of interest in this region already.
Our confidence in LIGHT's commercialisation is also borne out by the desire from the scientific and clinical communities for technical improvements in proton beam therapy. These include rapid proton beam modulation (direction, energy and dose), beam size and improved treatment planning and execution, all of which LIGHT is designed to offer.
Post-period end, in July, we announced that a consortium led by one of our longstanding investors, AB Segulah, provided additional financing to the Company through a £3.9m loan facility. At the same time we agreed with Bracknor to waive the requirement for the Company to drawdown the minimum of 10 tranches and declared that the Company would not intend to use the Bracknor facility in the future.
The support shown by our Swedish investors allows us to approach long-term financing options from a stronger position. We continue to assess additional long-term financing options and conversations have been encouraging, particularly in light of the reassurance that our continuing technological progress provides in terms of our ability to overcome the most challenging technical aspects of our development programme. We look forward to updating shareholders as these conversations advance.
Scientific and Operational expertise
With the need to deliver on both technological development and commercial roll-out into a clinical setting it is essential for us to have both scientific and operational expertise providing input at a Board level, ensuring that we continue to deliver to the expectations we laid out to shareholders in March 2017 and which we believe will be the catalysts for shareholder value.
Professor Steve Myers' contribution to the Board has been particularly welcomed given his hands-on experience as Executive Chairman of our fully owned subsidiary, ADAM S.A., and his past role as Director of Accelerators and Technology at CERN. Hans von Celsing, also appointed as a Non-Executive Director, has considerable experience in the business development of both radiation and proton therapy companies.
We also now benefit from the direct contribution at the Board level from Dr. Nick Plowman a key opinion leader in radiation oncology technology and clinical oncologist at St Bartholomew's Hospital and Great Ormond Street Hospital.
We are aware of the need to ensure that our Board composition is appropriate and provides us with the necessary technical, medical and commercial expertise to deliver on our ambitious plans to become a world-leading manufacturer of affordable, accessible and most effective next-generation proton therapy systems. We are also greatly encouraged to see the extent of support from our Board in their own shareholding interests in the business and the degree to which they continue to purchase shares.
In addition, the senior management team was reinforced by Ed Lee, who joined as Chief Operating Officer. Ed joined from Optivus Proton Therapy at Loma Linda University, site of the world's first and longest running commercial proton therapy centre. Dr. Jonathan Farr also joined us from the St Jude Children's Research Hospital, a world renowned institution in paediatric oncology, as Senior Vice-President of Medical Physics.
The Company recorded a loss of £6.78 million in the six months to 30 June 2017 (H1 2016: £5.34 million), with shareholder funds increasing to £32.01 million over the same period (H1 2016: £22.63 million).
Cash and cash equivalents at 30 June 2017 were £235,437, with working capital of £3.63 million, a post period financing agreement for £3.90 million and £3.05 million of the corporation tax R&D refund received.
The Board is having ongoing discussions with potential funders and remains confident that additional funds will be available as and when needed.
There is an increasing demand for proton therapy globally, with millions of patients who could potentially benefit from this technology. While the access to this technology remains scarce, there is a significant unmet medical need the LIGHT system is uniquely suited to provide.
We are in a prime position to provide a novel and disruptive technology that advances current methods of cancer treatment in the UK and worldwide. There is mounting evidence for the clinical superiority of proton therapy over traditional X-ray radiotherapy. This evidence will only increase as more proton beam centres are built and more patients are treated. LIGHT's modularity and linear design allow for mass production, shorter manufacturing lead times, easier installation/commissioning and offer both cost and clinical advantages.
The technological development of our LIGHT system remains on-track and importantly we have achieved the most challenging milestones in relation to the acceleration of protons, which has significantly reduced the overall technology risk of the accelerating system. Going forwards, we expect to update shareholders on newsflow in firing the proton beam through additional SCDTL modules, further news on the development of the PPS and on the directional dose delivery system.
Work at our Harley Street site remains on schedule and we believe we are in a stronger position to secure long-term financing, particularly as we continue to advance the technical development of our first LIGHT system. We continue to have strong commercial interest in future LIGHT systems.
We will continue to update shareholders on our progress as regularly as possible and remain confident that we are on track to deliver a world-leading proton therapy technology that will have a major impact on cancer treatments across the globe.
On behalf of the Board, I would like to thank our shareholders and everyone working towards our shared goal for their continued support and look forward to updating them further on our exciting journey.
Dr. Michael Sinclair
Unaudited
Audited
6 months to
Administrative expenses
(13,087,307)
Operating loss
Loss on ordinary activities before taxation
Loss after taxation from continuing operations
Discontinued operations
Loss for the period from discontinued operations
Loss after discontinued operations
Loss for the period
Equity shareholders of the parent Company
Exchange differences on translation of foreign operations
Total comprehensive loss for the period net of tax
Total comprehensive loss attributable to:
Trade and other receivables
Corporation tax R&D refund
Trade and other payables
Borrowings
Non-current liabilities
Share premium reserve
Share option reserve
Reverse acquisition reserve
Loan note conversion reserve
Exchange movements reserve
Accumulated losses
Equity attributable to shareholders of the Parent Company
Total equity funds
Cash flow from operating activities
Loss after taxation
Share based payments
Cash flows from operations before
changes in working capital
Change in trade and other receivables
Change in trade and other payables
Cash (used) / generated from operations
Corporation tax receipt
Capital expenditure on intangible assets
Purchase of plant and equipment
Cash flows from investment activities
Equity share capital raised
Convertible loan notes
Other short term loans
Intra Group Cash Transfers
Decrease in cash and cash equivalents
Cash and cash equivalents at beginning of the period
Cash and cash equivalents at end of the period
A copy of the unaudited interim accounts for the six months ended 30 June 2017 is available from the Company's website at www.advancedoncotherapy.com
BRR Media interview with Gabriel Urwitz, Exec Chairman of AB Segulah – Advanced Oncotherapy (AVO)
3rd August 2017 / Leave a comment
BRR Media interview with Gabriel Urwitz, Exec Chairman of AB Segulah. Click on the image to listen.
Advanced Oncotherapy (AVO) – Financing facility provided by significant shareholders
19th July 2017 / Leave a comment
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a consortium formed by AB Segulah and other investors has made available a £3.9m loan to the Company. The loan will have a two year maturity and a 12% per annum rolled up interest rate. The Segulah group includes AB Segulah, a significant shareholder of the Company, and a group of Swedish investors, including AFMS Radgivning Och Invest AB, Peter Gyllenhammar AB, Mijesi AB and Emendum AB. Segulah will be issued 15.6 million warrants with a strike price of 25p exercisable at any time over the next five years. Part or all of the loan can be redeemed at any time by the Company at 105% of par value. If an equity financing is carried out by the Company at or above 25p before the end of 2017 the loan can be converted into equity at 25p per share.
Agreement with Bracknor
Bracknor has agreed to waive the requirement for the Company to drawdown the minimum of 10 tranches. The Segulah loan, which is equivalent to three tranches, will entitle Bracknor to receive commitment fees on this amount only at a reduced rate of 2.5%. No further fees are owed to Bracknor.
The Company does not intend to use the Bracknor facility in the future. As part of these arrangements the Company will issue 7 million warrants to Bracknor. These warrants are exercisable at 25p and may be exercised at any time over the next five years.
Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy, said: "The Bracknor financing has been valuable to the Company. I would like to thank them for their flexibility in renegotiating its terms. I am particularly pleased to welcome the support shown by our highly valued Swedish investors and in particular the role that Segulah has played in arranging this new facility. Segulah was our first institutional investor and has participated in every financing since that date. The Company has benefitted not only from their financial support but also from advice grounded in their extensive international Med-Tech expertise."
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy (AVO) – Major Shareholder increases stake
21st March 2017 / Leave a comment
NOTIFICATION OF MAJOR INTEREST IN SHARES
download movie War for the Planet of the Apes 2017
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
3. Full name of person(s) subject to the notification obligation: iii
AB Segulah
4. Full name of shareholder(s)
(if different from 3.): iv
HSBC Global Custody Nominee (UK)
5. Date of the transaction and date on which the threshold is crossed or reached: v
6. Date on which issuer notified:
7. Threshold(s) that is/are crossed or
reached: vi, vii
8. Notified details:
A: Voting rights attached to shares viii, ix
if possible using
the ISIN CODE
Situation previous
to the triggering
Resulting situation after the triggering transaction
of shares
Number of voting
% of voting rights x
Direct xi
Indirectxii
Ordinary Shares GBP 0.25
GB00BD6SX109
B: Qualifying Financial Instruments
Type of financial
date xiii
Period xiv
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
date xvii
period xviii
rights instrument
refers to
% of voting rightsxix, xx
Total (A+B+C)
Percentage of voting rights
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
The 3,680,451 shares are held by HSBC Global Custody Nominee (UK) under direct control of AB Segulah.
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
14. Contact name:
David Navas, AVO plc
15. Contact telephone number:
Advanced Oncotherapy (AVO) – Significant Shareholder Dealing
29th December 2016 / Leave a comment
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that AB Segulah, a significant shareholder of the Company, today purchased 150,000 ordinary shares of 25 pence each in the Company at a price of 66 pence per Ordinary Share.
Following this transaction, AB Segulah now holds 3,219,451 Ordinary Shares representing 4.44% of the issued share capital of the Company.


DataConvert is a DNA data conversion tools.
Edit by Brothersoft: Convert any format of DNA or protein data to formats usable in major analytical software. you can free download DataConvert 1.0 now.
Please be aware that Brothersoft do not supply any crack, patches, serial numbers or keygen for DataConvert,and please consult directly with program authors for any problem with DataConvert.


text:
The Chronic är rapparen och producenten Dr. Dres första album i eget namn, utgivet 1992 som första albumet på Suge Knights skivbolag Death Row Records.

Skivan blev en enorm framgång och introducerade g-funk, som kännetecknas av samplingar från gamla funkinspelningar, långsamma melodiska basgångar och vinande synthesizerljud. Liksom i fallet med Dr. Dres tidigare projekt N.W.A. är vanliga teman våld och sexism samt negativa kommentarer kring Dres tidigare samarbetspartner Eazy-E.

Albumet blev som bäst trea på Billboard 200.

Låtlista
"The Chronic (Intro)" - 1:58
"Fuck Wit Dre Day (And Everybody's Celebratin')" - 4:52
"Let Me Ride"     	 4:21
"The Day the Niggaz Took Over" - 4:33
"Nuthin' but a "G" Thang" - 3:58
"Deeez Nuuuts" - 5:06
"Lil' Ghetto Boy" - 5:29
"A Nigga Witta Gun" - 3:53
"Rat-Tat-Tat-Tat" - 3:49
"The $20 Sack Pyramid" - 2:53
"Lyrical Gangbang" - 4:05
"High Powered" - 2:44
"The Doctor's Office" - 1:04
"Stranded on Death Row" - 4:47
"The Roach (The Chronic Outro)" - 4:37
"Bitches Ain't Shit" - 4:48

Album av Dr. Dre
Musikalbum 1992
Amerikanska debutalbum
Amerikanska hiphopalbum
Album producerade av Dr. Dre

redpajama_set_name: RedPajamaWikipedia


Sorry, now only i see that for Smartphone it is version 1.10.
So this 1.51 will not work on my phone.
freekgubbels wrote: I run 1.10 but since today the application crashes and doenst show the photos. Probably the new version will resolve these problems.
Youhave a crash at the startup?
Did you aware that XnView Pocket 1.51 is a glitch? For many years.
1)Tools>Adjust doesn't save image. Always "Problem to save the file!". Other tools save file w/o error.
2)Toolbar button "Fullscreen" in image view mode doesn't switch to fullscreen. Showing browser for half second and make nothing.
3)Toolbar button "Information" in image view mode always grayed and produce "disabled" sound only.
4)Buttons mapping doesn\t work properly. I can map some buttons in options (Record for exam.) but system action start when view image.
5)Tap and slide doesn't work in image view mode (non fullscreen).


Name of restaurant: Zafran Pot. The name says exactly what the restaurant is about. Zafran is saffron. And pot is, well, a pot — a big one in which the restaurant's specialty, Hyderabadi dum biryani, is cooked. The saffron's job is to color the biryani rice yellow.
Where you're eating: In a corner mall on Venice Boulevard in Culver City. This strip of Venice has become a center of serious Indian regional food — the Kerala restaurant Mayura (a regular on Jonathan Gold's 101 Best Restaurants list) is next door, and just east is the Chennai vegetarian restaurant Annapurna. Zafran Pot opened in May, taking over a Punjabi restaurant.
What you should eat: The biryani because this is the most authentic Hyderabadi dum biryani on the Westside and rivals anything in Artesia's Little India. Dum is the style of cooking; the meat is marinated overnight, then placed raw in the pot and covered with half-cooked basmati rice. Saffron, heated with milk, is sprinkled over the top. The sealed pot cooks on high heat, then medium, then low, with a griddle underneath to keep the meat from burning. The three types of biryani are chicken, made with organic halal chicken; a vegetable biryani; and lamb, which is available only on weekends. Each is seasoned differently. The lamb is spicier and more tangy, and its marinade includes coconut milk.
What you won't get anywhere else: Chicken chops — chicken in a green sauce with spinach, cilantro, onions and spices. The chicken is cooked dry or moist, like a curry.
For smokers: Actually, it's the chicken tikka masala that does the smoking. A steel bowl containing a small live coal is placed in the pot of sauce, then the pot is covered for 10 minutes of smoking. The sauce contains cream, cashews, tomatoes, onion and spices including paprika — smoked paprika, of course.
Who's cooking: Sneh Lata Gumidelli, from Bangalore. "I am not a professional, to be frank," she says, but she has catered and did well as a home cook. The chicken chops is a family recipe. The Hyderabadi biryani had input from family, chefs in India and her husband, Santosh, who is from Hyderabad. "I want the authentic to be present in whatever dishes I make," Gumidelli says, and so she grinds all her own masalas. She's health conscious too: She makes the peanut gravy salan that traditionally goes with Hyderabadi biryani with pumpkin seeds instead of peanuts for those with nut allergies.
What you're looking at: A tiny restaurant with a handful of tables and a display of cooked dishes that isn't a buffet. They're the choices for combo plates, composed of either four or six items.
A sweet ending: Skip the gulab jamun and get khubani ka meetha. This is a Hyderabadi dessert of small whole dried Indian apricots soaked, boiled, sweetened and scented with cardamom, then dished with vanilla ice cream.


The Representational Art Conference of 2018—also known as TRAC2018—was held from the first through the fourth of May in the city of Leeuwarden, the Netherlands. TRAC's motto 'A movement is sweeping the art world' welcomes the dialogue of exciting ideas and new developments in 21st Century representational art. The comprehensive term 'representational art' is defined by TRAC as including a wide variety of skill-based work in a broad range of techniques based upon recognizable expressions of reality, which—despite being declared dead and irrelevant by the 'art police'—is obviously experiencing a slow but steady renaissance. TRAC is one among several important movements and institutions that is currently addressing the neglect of critical appreciation regarding representational art and promoting its quality, significance, and academic standards through its non-doctrinaire events.
Artists, scholars, writers, educators, lecturers, historians, philosophers, critics, museum and gallery professionals, and collectors gathered from all over the world to attend panel discussions, discourses, paper presentations, exhibitions, and demonstrations. Special importance was given to the exchange of ideas regarding the assessment of artistic quality with special focus on the value and reach of skill-based art education. Art schools from around the world were invited with an eye on bringing them together in an international league. One of the many interesting subjects posed at TRAC was regarding the role of the representational artist in the 21st Century and how skill-based art should progress in order to reclaim its relevance in this new era.
Mostly taking place within the WTC Leeuwarden's conference facilities, the activities often overlapped each other in time which meant attendees had to choose which topics most spoke to them—on several occasions I felt torn between attending separate events, wishing I could be in two places simultaneously. The calendar offered a treasure trove of fascinating topics presented by prominent speakers, distinguished philosophers, and world-famous artists—it is a rarity to encounter so many exceptionally erudite people in one location and it felt as a gift to be able to engage and socialize with them.
Luckily the Dutch weather cooperated by not raining for a change, as not all activities took place indoors. There were outings too, such as a quaint excursion through the canals of Leeuwarden on barges that took us to attend the opening of the Classical Art Exhibition at the Frisian Gallery Zaailand, inaugurated by Peter Trippi, very close to the Fries Museum where an exhibition of M.C. Escher is being held. On the last day we also visited three museums, but more about that later.
As a result of this stirring experience, I felt inspired to write about it—to, in a sense, relive it. The thing is, I cannot possibly do justice within this limited space to adequately describe these four splendid days so I've resigned myself to writing a curtailed overview in the hope it will inspire readers to attend the next TRAC. A special thank you goes out to Annelies Meester for her hard work and friendly hospitality during the conference. I ask forgiveness from those whom I neglect to mention by name but who contributed to this conference with their sheer hard work, intelligent insights, powerful dialogs, beautiful art, and warm camaraderie.
From the moment I arrived there was a palpable excitement in the air, probably partly due to the fact that this conference was a safe haven for representational artists who could fully focus on important matters at hand instead of having to defend their stylistic choices. TRAC2018 created a sense of community, identification, and inclusion, which is not only emotionally important but also highly energizing for realist artists like me who spent most of their time working behind closed doors.
As expected within group dynamics, there were clashes of egos and, more importantly, collisions between contrasting ideas which in turn flamed intense debates that made participation so much more stimulating and thought-provoking. Obviously, there wouldn't be a need to get together if everybody happily agreed on everything from the start. Mostly there was abundant openness and willingness to understand each other and put new ideas into action. This, to me, is what TRAC is about. But don't take my word for it—I'll let others speak about their TRAC2018 experience.
Both Frima and I were impressed by the eloquent dissertation given by Mandy Theis Hallenius about her proactive efforts to support and disseminate skill-based art learning to new generations, and the powerful treatise by Jennifer Sendall on how to strengthen the case for representational art as a tool to construct a more creative, ecological, and mutually beneficial society.
José Manuel Infiesta, Director of the European Museum of Modern Art or MEAM in Barcelona, Spain, participated in an interesting panel discussion together with Michael Pearce, Jorge Egea, Peter Trippi, and Virgil Elliott. They spoke about the assessment of art, the values and criteria of quality, art criticism, promotion, and ways to restore the public respect for skill-based art. Infiesta is an influential advocate for figurative artists, distinguishing his museum from all others by exclusively collecting figurative work by living realist artists.
I want to shine a spotlight on artist Gezien van de Riet who kindly invited me to attend TRAC2018 and whose ready smile and quick mind light up any room. After attending two previous TRAC summits and seeing the significance of an international movement reinforcing and enriching contemporary classical art, van de Riet presented the idea of having this conference in Europe to Tom Hageman, artist and founder of the Classical Academy of Fine Art in Groningen. They were instrumental in bringing TRAC to the city of Leeuwarden, the European Cultural Capital of 2018.
Gezien van de Riet held a joint keynote lecture with artist, author, and the world's foremost authority on Rembrandt, Ernst van de Wetering. In their presentation, van de Riet passionately contested the persistent notion that naturalistic realism is nothing but unimaginative imitation, after which van de Wetering underpinned the aforementioned thesis by presenting Rembrandt as a rational artist who made clear choices in regards to his painting methods, style, and use of light and shadow.
We began the final day of TRAC with an engrossing keynote lecture by Joseph Bravo, which turned into an active and passionate group discussion thanks to his talent for including others in the conversation. Unfortunately, the discussion had to end after an hour because we needed to catch a bus tour that took us to three museum exhibitions. We visited the exhibition Romanticism in the North at the Groninger Museum, and then went on to see American Dream—a delightful survey of American realism and photorealism for which Peter Trippi had been advisor to the curators—jointly held at the Drents Museum in the Netherlands and Kunsthalle Emden in Germany.
That evening TRAC2018 ended with a closing dinner hosted by the Municipality of Leeuwarden at the WTC Hotel where tables filled with animated attendees shared their thoughts and impression of four wonderful days, exchanging hugs and contact information, and promising to stay in touch. Dinner was briefly interrupted by observing two minutes of silence held annually on May 4th for the Dutch Remembrance of the Dead (Dodenherdenking) honoring our war casualties.
Real life friendships made, projects planned, ideas exchanged, minds fed, brains stretched, mental and creative batteries recharged—it was truly a meaningful, energizing, and inspiring experience. I strongly urge all artists to attend the next TRAC—whenever and wherever it may take place in future. See you there!
TRAC2018 was sponsored by California Lutheran University President Dr. Chris Kimball's Arts Initiative, the Art Renewal Center, the Classical Academy of Fine Arts, the City of Leeuwarden, Classical Salon, Grafisch Atelier Friesland, The Fine Art Collective, Bekking & Blitz Publishers, Achmea Centrale Dienstverlening, and Stichting Beringer Hazewinkel.


At Rolling River Rampage VBS, your students will discover an interactive, energizing, Bible-based program that will give them an opportunity to experience the ride of a lifetime with God. During Vacation Bible School at Rolling River Rampage: Experience the Ride of a Lifetime with God, your students will become rafters and explore how to serve God and God's mission for their lives.
After a high-energy Opening Assembly, the Rafters make their way to the Bible Story Station, Interactive Bible lessons reveal Rapid Reminders to equip your Rafters for an active life with God. Your Rafters will discover a Rafting Ready Verse that will remain with them in their faith, long after VBS.
The students will expand on what they've discovered by participating in a variety of activities: making art projects at the Craft Station, singing new music, exploring at the Science Station, participating in recreational activities at the Recreation Station, and enjoying tasty snacks at the Snack Station.
Parents, grandparents and friends are invited to join us in the Closing Celebration each day from 11:00am to 11:30am, because that's when we'll be having a daily celebration you wont want to miss.
So mark these dates on your calendar: July 23-27, 2018. The fun starts at 9:00am and will end at 11:30am. Call this number, 239.995.0133 to register your children for this life-changing adventure, or fill out a registration form.


text:
Marco Fertonani (Génova, Italia, 8 de julio de 1976) es un ciclista italiano.

Debutó como profesional en 2002 con el equipo Phonak.

Palmarés
2004
 1 etapa de la Vuelta al Lago Qinghai

2006
 1 etapa de la Vuelta a Castilla y León

Resultados en Grandes Vueltas

—: no participa
Ab.: abandono

Referencias

Equipos
 Phonak (2002-2004)
 Domina Vacance (2005)
 Caisse d'Epargne (2006-2007)
 Caisse d'Epargne-Illes Balears (2006)
 Casise d'Epargne (2007)

Enlaces externos

Ciclistas de Italia
Casos de dopaje en ciclismo
Nacidos en Génova


text:
Damien Molony Live Q & A | BBC Being Human Blog
Ask Damien Q & A | BBC Being Human Blog | 10 February 2013
Damiens' responses to fan questions in a live Q & A on the official Being Human blog, hosted by Stephen Saul on 10 February 2013
timeandtide
Which Hal do you prefer to play: suave, in control, blooded-up Hal or the buttoned-up, off-the-blood Hal?
Hi timeandtide, cop-out answer, I love playing Hal, full stop. I love fighting his present-day battles, be they the struggles of bloodlust and his self-doubt, his shame at what happened to Alex, his suppression of his horrific past and his endless need to be 'in control'.
But then I love exploring his history, being 'out of control', the confidence, playing with his prey. And of course, there are other sides to Hal which I REALLY loved playing that haven't been shown on Being Human… yet.
adam_c
Hi Damien 🙂 Did you feel any pressure taking over from Aidan Turner as the main vampire on the show?
Hello Adam (the 'C' stands for Craig, as in Roberts, right?) I did feel some pressure, of course. How do you follow Aidan? How do you replace Mitchell? He was such a brilliant character, and actor, adored and mourned. I had a responsibility to the writers, to the fans to not let the side down.
I tried not to think about 'pressure'. I didn't go around set thinking "oh, I can't eat toast in this scene because Mitchell ate toast", or "oh Mitchell had long hair, so I should have short hair". I just tried to be true to Hal as created by Toby, to bring my own interpretation of 'vampire', and then let the fans make up their own mind.
JakeHamblin
Do you think you are like Hal? Not in a vampirey way, In an OCD, Radio 4 kind of way?
Good question, JakeHamblin! I'd like to think I'm a lot more relaxed and easy-going than Hal, not sure my vocabulary is as accurate as his and my house certainly isn't as tidy. Basically, I don't own Marigolds. And I would never drink the blood of a girl I was taking out on a date. But, I do have some little tics especially when it comes to my scripts, music collection.
The closest I get to being a vampire suffering from blood-withdrawal, is (obviously) before I have a coffee in the morning… watch out…
Hiya Damien! Firstly I think you're amazing and adore watching you as Hal in Being Human! My question: If asked, would you ever consider playing The Doctor (Doctor Who) or starring as a future companion?
Thanks Jess, that's very kind of you. The Doctor is one of the most iconic parts for an actor to play, up there with Sherlock Holmes, James Bond, it is such an epic series. Following in the footsteps of so many great actors, it would be an honour to play The Doctor… wow, goosebumps! What about a Being Human/Doctor Who spin-off?
katiess
Hey, Damien! What's it like to work with Michael Socha?
Hey Katiess! He's not a nice person, the eyebrows are fake… joke! I absolutely love him (not 'LUV' him, real properly LOVE him), he made me laugh every single day we were on set together on Series 4 AND 5 and he is one of the best actors that I have ever worked with. I even made a rap about him, but I'm not telling you it… it's just for him.
annajedwardxo
Hey Damien, just wanted to say I LOVE Hal so much!
Anyway my question is: If you could bring someone back from a previous series who you haven't worked with who would it be and why?
xxx
Thank you Annajedwardxo. That's a tough one, over those first three amazing series, there's so many! Herrick DEFINITELY, Cara too. I would've loved to see if Mitchell and Hal ever crossed paths. And I'd really liked to have done scenes with George. And Graham and Sasha too. I could keep going…
Hi Damien, you've probably been asked this a hundred times before but what was it that drew you towards acting, and where would you place Hal on a list of all the characters you've played in your career?
Toby? Whithouse? Is that you?! I've wanted to be an actor all my life. Why? I suppose, I love films, I love the theatre. I love telling stories to people. I love tricking people into believing that I'm someone else. And I love immersing myself into new worlds with every character I get to play.
So with Hal, learning about addiction, researching Orsha for Hal's prequel etc. Finding the reality in a supernatural story and sharing that with an audience. And Hal is easily one of the best characters, especially because I've had the opportunity to play so many different aspects of him… in so many different environments, past and present.
Indigo Blues
Hi Damien! Q: what is the most hilarious things you guys were up to doing down time on a shoot? Love, Indigo x
Thanks Indigo Blues. Trailer-Roulette was a highlight, as was filming the Online Exclusive Episode due out after Episode 3 next week.
Actually, in the first Online Episode this series, in one of the takes, the sandwich that Michael eats is a jam sandwich with about three spoonfuls of mustard in it. Michael is so good, that you never even notice. There are lots of jokers on set, leaving corpses in trailers and hiding under beds during scenes. It's a brilliant show to work on.
lakka30
Who's your all-time favourite TV or film ghost/vampire/werewolf?
Hey Lakka30, obviously Alex, Hal and Tom, with Annie, Mitchell and George running a very close second… I'm biased. 😉
Ghost: do I be a wuss and say Truly, Madly, Deeply? Or go scary and say the spirits at the end of Raiders of the Lost Ark? Banquo's ghost has always freaked me out too.
Vampire: I've always liked Danny Huston in 30 Days of Night, and Dracula (1931) is a must-see.
Werewolf: Honestly, I think the BH werewolf transformation sequences are the most excruciatingly uncomfortable scenes to watch, they make it look so real, so painful, and show that being a werewolf is not a glamorous superpower but a life-changing curse. An American Werewolf in London is always a winner too.
sedavison
If Hal had been a ghost, what do you think would have been his 'unfinished business'… and what would yours be?
Great question! Hal's unfinished business would definitely be to take over the world, Mwahahaha! My unfinished business (aside from working with Tarantino, Spielberg, Haneke and Scorsese on a new trilogy of films… yet to be achieved, let's say) is, I don't know, to score a goal at the Nou Camp. I'm not THAT into football, there's just something about that ROAR of the crowd…
Tiggy1991
My question for Damien… Its sooooo sad that Being Human is ending (I don't know what I will do with my life now!!), what has been the best thing about working on a fantastic show like this?
Hi Tiggy1991, I know, it is terribly sad that the series is ending, but firstly, what an ending and secondly, what an incredible five series there have been.
I've been so lucky to play such a brilliant character, to work with so many ridiculously talented and inspiring people; all the actors, Phil & Dan, Toby and all the producers and writers, all the crew. All of those people have become friends. It has been a brilliant two years of my life and I have a lifetime of great memories from my time with them all.
BetsyL
Hello Damien, my question is that out of all the episodes you've been in, which was your favourite to film?
Hi BetsyL, I loved Series 4 Ep 7 and all my scenes with Andrew Gower (Cutler). I also loved Episode 2 last year, all my scenes with Leo and Pearl and moving into the house. And the scenes with Mr. Snow were great fun too. Series 5 this year, I loved doing Episode 1, Episode 3 was HILARIOUS fun to film, Episode 5 was brilliant to work on, so well-written and a rollercoaster for the three of us and Episode 6, well… my favourite days on set… EVER.
deeee
If you could have 3 dinner guests dead/alive, who and why? 🙂
Hi Deeee, easy… 1: Steven Spielberg, my favourite director. I'd learn from him, listen to every story he had to tell about the making of all his films, and then ask him for a job. 2: Brian O'Driscoll, the Irish rugby captain. He is a massive inspiration for me. And 3: Marlon Brando, just to watch him eat.
Su hemming
Another one, if you could have taken any prop from the show to keep, what would it be? Xx
Su, we have a brilliant Props team, obviously. They gave me the massive 'Show No Mercy' poster from Series 4, still trying to find a place where I can legitimately hang it without looking a tad strange to visitors. They also gave me Hal's domino. And a set of house-keys. And a pool-cue…
What I really wanted, but didn't get: the tea-maker/alarm clock things beside all the beds, I really wanted one of those. The organ would've been pretty cool too.
We all love Hal. Have you based him on anyone in particular?
Hello Frances. Hal is based on a few different people I've met, some characters from films (vampire films and others). And I did a lot of research on addiction and recovery. You have to be a very good at people-watching in this profession.
AmyLisaa Please
Tell us, what /does/ Kia-Ora do to Hal?
AmyLisaa, this is one of the questions I get asked the most. Here's a question for you: what do YOU think it does to him? I've always had a theory that Kia-Ora makes *THIS POST HAS BEEN REMOVED BY SITE MODERATORS*
Hi Damien, I'm aspiring to be an actor myself, I'm in my final year of sixth form and I'm hoping to go onto University to carry on studying Drama. I was wondering, do you have any tips for young actors like myself?
Hi Jade. The main tip/note I always give myself is: "Listen to the other person in the scene." Immerse yourself in the world of theatre and film, join and support amateur theatre companies. Read plays. Go to the theatre, watch TV and films. Have role models, which actor would YOU like to be like? Why?
Peacock_Gemstone
We've seen Hal in lots of different costumes/clothes from the army uniform, THE tweed suit, Leather Jacket and who can forget Marigolds… what has been your favourite?
Hi Peacock_Gemstone, we have an amazing costume team on set. And they've played such a big part in helping to bring Hal to life. My favourite costume is probably the tweed suit: socks, shoes, trousers, waistcoat, shirt and jacket. All together, when I put them on, I am Hal. The suit Hal wore on that date with Alex was great too. And there are two costumes in Episode 6 this year that are my favourites for Series 5!
Paula Mc
Hi Damien, how are you? You are fab as Hal and my question(s) are: Which film adaptation from a book would you star in and why? Thanks and take care.
Thanks Paula Mc. I would love to play one of the devils in Paradise Lost. Milton's book is an incredible piece of literature, from the language to the Charles I parallels to the epic story. I'd love to play Belial, give Captain Hatch a run for his money.
Jesscarroll
If you hadn't become an actor what else would you like to have done?
Hi Jesscarroll, if I hadn't become an actor, I would have found someway to be involved in the arts, backstage or on set. I couldn't see myself anywhere else.
Georginaaaa
DAMIEN! My question is: What cheese would you describe yourself as?
Georginaaaa, I've just had some taleggio on toast for supper. I am definitely Taleggio, I am cool and calm in cold environments but put me in a hot climate and I melt and subsequently burn faster than you can apply your Factor 50!

redpajama_set_name: RedPajamaCommonCrawl


Speaking from his knowledge of the Cambridge marketplace Ilya Rasner was a recent guest on Real Estate Boston with Rick Scherer and Ali Alavar on WBZ News Radio.
When acting in the interested of a buyer Ilya Rasner wants his clients not to be fooled by the price. Boston Herald article, "Shop Strategically, Say Agents" quotes Ilya Rasner as saying, "Pricing is not a pure science. As a buyer, you shouldn't always expect that the place is priced correctly."
That's where The Rasner Group's experience and knowledge of the market can assist you in finding not only the right home but one that you pay the right price for.


The 12th Century AD tunnel was built by the Crusader Templars to connect their fortress on the south-west side of Acre to the harbor on the south-east side.
The Crusaders of the Templars order settled in Acre in the 12th Century AD after the fall of Jerusalem, and built a fortress on the south-west corner of the old city of Acre. They also cut a 350M tunnel into the rock in order to connect the fortress to the port, located on the south-eastern side. The secret tunnel was recently discovered, cleaned and opened to the public.
The eastern entrance is located near KhanAl-Umdan. The Khan is located near the marina, on the south-east side of the old city. During the Crusaders times, it was the site was an internal anchorage of the port of Akko.
The western entrance (or exit) is located near the modern light house, where the Templar fortress was once located.
A ticket to the tunnel can be purchased in conjunction to a tour of the Knights hall.
The map below shows the path of the tunnel, between the area of the lighthouse (on the left side) to the area of the Crusaders port (on the right side).
In 1099 AD the Crusaders conquered Jerusalem, and called the Temple-Mount as "Templum Domini", turned the Dome of the rock to a church, adding a cross on the dome. The Templar Knights military-religious organization was established in 1118, and named their organization after the temple: the guards of the temple. Their task, as defined by the pope, was to protect the pilgrims and patients that visited the Holy Land.
The Crusaders were driven out from Jerusalem by Saladin in 1187. The Templars retreated to Acre - the Crusaders last stronghold in the Holy Land - and built their central fortress and palace on the south-west side. The fortress, now gone, was protected by mighty walls and four towers. They also cut a 350M wide tunnel under the rock from the fortress to the south-west side of the city, in order to provide a concealed access to the Crusaders inner port, where Khan al-Umdan was later constructed. The tunnel was cut into the rock as a semi-barreled arch, and its ceiling was reinforced by hewn (cut) stones.
In 1291 the city was taken by the Mamlukes, and was completely destroyed - degrading Acre to a small neglected city until the end of the 18th Century. Over these years, the existence of the secret tunnel was forgotten.
The tunnel was rediscovered by chance: In 1994 a woman resident, living above the tunnel, complained on a blocked sewage. While searching for the underground block, the tunnel was discovered. It was then cleaned out from more than 800 years of dirt and filth. After adding a walkway, lights and access, the tunnel was opened to the public in 1999.
A view of the tunnel is seen below. The top part is reinforced by hewn (cut) stones.
A split of the tunnel to double arches. The right (south) tunnel is still under excavations and restoration.
The walk along the tunnel is recommended, and is one of the new sites added in Acre in recent years. There are more hidden secrets under the houses of the old city, and continued explorations and reconstructions will continue to enhance this beautiful ancient city.


eDataSource is the premier source of email performance insights and deliverability technology. Ensure that every email campaign is reaching your customers' inboxes with eDataSource. Comprehensive email marketing tools, providing accurate deliverabilty data and analysis.
eDataSource clients engage us for our state-of-the-art database and tools, for our deep and seasoned expertise, and for the insights and direction we can provide. We accurately monitor and measure inbox performance, isolate and diagnose any problem areas, and provide guidance in addressing those problems. Our competitive intelligence allows for the identification of opportunities to improve program performance.
eDataSource offers a singular combination of rich, accurate, highly accessible email delivery and engagement data, reflecting real consumers; deep industry knowledge applied by a seasoned, client-focused team; key strategic partnerships with Cloudmark, Persado, and Litmus; and a broad, sophisticated product array supporting both competitive intelligence and deliverability monitoring, diagnostics and authentication.
eDataSource clients engage us for our state-of-the-art database and tools, for our deep and seasoned expertise, and for the insights and direction we can provide. We accurately monitor and measure inbox performance, isolate and diagnose any problem areas, and provide guidance in addressing those problems. Our competitive intelligence allows for the identification of opportunities to improve audience and program performance, through an understanding of comparative audience sizes, campaign deployments, degrees of targeting, creative execution, inbox deliverability and message engagement.
eDataSource offers a singular combination of rich, accurate, highly accessible email delivery and engagement data, reflecting real consumers; deep industry knowledge applied by a seasoned, client-focused team; key strategic partnerships with Cloudmark and Persado; and a broad, sophisticated product array supporting both competitive intelligence and deliverability monitoring, diagnostics and authentication.
eDataSource was founded in 2003 as the first and only email competitive intelligence company using real, live consumer panel data allowing email marketers to view and assess performance of competitor emails. The visibility and insight provided by this intelligence would fundamentally change how email marketers, publishers and service providers compete in the inbox.
Panel data testing starts within the eDataSource platform interface to increase the value of competitive insights.
Successful panel testing leads to acquisition of Boxbe's assets. Real-time consumer behavior monitoring achieved with a complete rebuild of data processing.
Competitive Tracker launches as the first real-time, competitive platform using performance insights from live consumer inboxes.
Inbox Tracker is released, the first deliverability monitoring platform based on real consumer behavior. Design Tracker (powered by Litmus) launches as a pretesting tool for Inbox Tracker.
Inbox Tracker 2.0 launches, turning what was formerly a monitoring tool into a comprehensive, solution-driven, deliverability platform.
DeliveryIndex.org is launched, premiering the only real-time, actionable inbox placement benchmark. Now anyone can get a free peek into their deliverability performance with the smartest measurement model on the market.
Inbox Tracker, Cloudmark® Edition is released, supercharging the tool with live consumer feedback from one of the largest global networks in the world.
Reputation Advisor launches, the first fully automated tool to check over 100 variables affecting deliverability in 5 categories.
eDataSource launches the first-ever consumer inbox monitoring for a total of 43 global ISPs. In addition to the "big 4" domains already tracked (Gmail/Outlook/Yahoo/AOL), the 39 newly added ISPs include important operators like Comcast, Mail.com, Optimum Online, Charter.net and Spectrum/Time-Warner Cable. No other players in the email tracking space offer anything like this combination of data-depth and breadth of ISP representation.
Reputable Sender Accreditation Program launches, the most effective and cost-efficient whitelisting program of its kind. Subject Line Advisor (powered by Persado) launches, mapping emotional profile & performance data.
Subject Line Predict (powered by Persado) launches, allowing users pre-test and predict performance prior to deployment. Competitive Insights Extension is released on the Google Chrome store.
Google announces sweeping policy changes, restricting access to all 3rd party email apps. eDataSource announces the Enhanced Virtual User Network (EVUN), the most powerful replacement available in the industry for visibility into Gmail inbox deliverability performance.
The eDataSource platform and technology continue to expand rapidly and provide strong competitive advantage. We've introduced over 100 product enhancements in the past year alone. Our product development roadmap involves continuous upgrades to product functionality, including DMARC Reporting, Email Explorer, and User Journey Mapping.
eDataSource empowers brand marketers, email service providers, and digital agencies with the deepest, most accurate, and easily accessible information to improve critical success metrics of their marketing programs. Contact one of our experts today for a free demo and see how our best-in-class products and solutions can help you own the inbox.


The-Gardens Greyhound race results is the ultimate guide to find detailed The-Gardens race results for Greyhound racing Australia.
WELCOME TO NEWCASTLE GREYS MDN. . .
SADLY MISSED NEVER FORGOTTEN M. . .
LADBROKES CHALLENGE Ladbrokes . . .


All conference attendees will be required to pay a registration fee of $10 to ensure a place for lunch.
This may be done through PayPal. Please follow this link. You will have to create a free account to transfer the money. You should then enter "penpiano[at]yahoo.com" as the recipient of your $10. We're sorry the link does not set up the transaction more directly: the proprietary nature of Wikidot disallows a direct link to a PayPal transaction.
If you pay this way, we will confirm having received your payment, so if you do not hear from us, please write to statesofcrisis[at]brandeis.edu.
If PayPal is not a payment method you feel comfortable with, please send a check. Email if you'd like the proper address. If you are a Brandeis student, it may be easier for you to simply give the money to our treasurer, Lisa Rourke; cash or a check will do in this case.


text:
Black Friday London Theatre Offers
Black Friday London Theatre Sale
Venue: London Theatres
In partnership with WestEndTheatre.com, Visit Gay London is running its annual BLACK FRIDAY LONDON THEATRE SALE.
Check out over 40 West End shows that have ticket offers, including the fabulously camp musicals & Juliet at the Shaftesbury Theatre, Mamma Mia! at the Novello Theatre, Heathers The Musical at the Other Palace theatre, and Bring It On! at the Queen Elizabeth Hall.
If you love a diva experience then Tina – The Tina Turner Musical at the Aldwych Theatre is also part of the Black Friday sale.
Blockbuster musicals that have recently come back to the West End include Les Miserables at the Sondheim Theatre and The Phantom of the Opera at Her Majesty's Theatre – both of which have been refreshed and revitalised and are well worth going back to. Also check out special prices on DEAR EVAN HANSEN, The Book of Mormon, Mary Poppins, Wicked, Come From Away, Jersey Boys and more.
Also why not see a play?! The National's sold out production of The Ocean at the End of the Lane is playing at the Duke of York's Theatre, and the stage adaptation of Life of Pi has just started at the Wyndham's Theatre. Plus see a comedy – from hilarious new show Pride & Prejudice (Sort of) at the Criterion Theatre, to The Play That Goes Wrong at the Duchess Theatre.
Book the Black Friday Sale by checking out the offers here >


Okay, here we go: It was actually pretty good. You definately have the freedoc format down solid. Just make sure that you leave the revision tag out of the header when you create a document, so it doesn't leave an mm/dd/yyyy there.
I redid the document for reference, leaving you as the author and implementing the chart format you asked about. You can modify the document to how you see fit. I did this in two hours: my grammer, information and whole approach to explaining it may be off. But it's just to demonstrate the amount of detail you should consider when documenting a language element.
Ok, I see what you mean, Ill try to make my docs alot more informative.
It also might help to..
How would your chart output? Something like this?
WAIT!! Never mind!!! You SHOULD use <row> in that chart.
k, have updated my docs + written one for NOT. Havent uploaded anything yet, will do when I get home from work in about 4 hours.
Just one question, how do I move files in the cvs folder? Should i cut n paste the file into the new directory and ADD it, n then COMMIT the changes? Im just afraid cvs will duplicate the file so the latest changed file gets added to the Complete folder, but the old one still stays in the Incomplet folder..
I'm not sure either. I had trouble with that.
Do a regular local filesystem copy; commit the copy; do a CVS Remove on the original.


We can scope and advise your vessel and implement your unique Water Safety Plan.
The Maritime Labour Convention (MLC 2006) has come into force and sets out regulations specifying the need to maintain high quality drinking water standards onboard ship which protect crew from waterborne health risks.
Location – 1-2 day visit on-board depending on the size of the yacht.


text:
Global Capabilities
Ediscovery Solutions
NPC: The On-Site eDiscovery Solution
Digital Forensic Services
Office 365 Migration & Management
Merger Authorisation & Antitrust
Regulations & Investigations
43 offices in 20 countries.
The eDiscovery Blog
New York Hilton Midtown
What is eDiscovery?
Stay on top of the latest in eDiscovery with updates from KLDiscovery.com.
KrolLDiscovery rebrands itself to become KLDiscovery
KLDiscovery will serve as the parent company and brand for the global legal technologies business while Ontrack will once again serve as the data recovery brand
McLean, Va. – January 2, 2018 -- KrolLDiscovery today announced that it will become KLDiscovery, further distinguishing itself in the ediscovery and information governance spaces. Additionally, Kroll Ontrack will rebrand as Ontrack. Both of these brands will continue to offer best-in-class technologies and services to global clients.
"The launch of KLDiscovery and Ontrack illustrates our commitment to developing the best ediscovery and data recovery solutions for our clients," said Chris Weiler, Chief Executive Officer. "These new brands continue to honor the technical heritage our company has created over the last 30 years and builds on the strength of our people in solving ediscovery, information governance and data recovery challenges."
The KLDiscovery brand for legal technologies and the Ontrack brand for data recovery capture the organization's 30 years as leaders in their respective industries. In addition to building innovative proprietary technologies, including robust processing capabilities and patented technology assisted review, KLDiscovery has significant experience with Relativity as the first provider to license the tool. Ontrack, a KLDiscovery business, continues to be the global market leader in data recovery, email extraction and restoration, data destruction and tape management.
About KLDiscovery
KLDiscovery provides technology-enabled services and software to help law firms, corporations, government agencies and consumers solve complex data challenges. The company, with offices in 40+ locations across 20 countries, is a global leader in delivering best-in-class eDiscovery, information governance and data recovery solutions to support the litigation, regulatory compliance, internal investigation and data recovery and management needs of our clients. Serving clients for over 30 years, KLDiscovery offers data collection and forensic investigation, early case assessment, electronic discovery and data processing, application software and data hosting for web-based document reviews, and managed document review services. In addition, through its global Ontrack Data Recovery business, KLDiscovery delivers world-class data recovery, email extraction and restoration, data destruction and tape management. KLDiscovery has been recognised as one of the fastest growing companies in North America by both Inc. Magazine (Inc. 5000) and Deloitte (Deloitte's Technology Fast 500) and CEO Chris Weiler was recognised as a 2014 Ernst & Young Entrepreneur of the Year™. Additionally, KLDiscovery is a Relativity Certified Partner and maintains ISO/IEC 27001 Certified data centres around the world. For more information, please email info@kldiscovery.com or visit www.kldiscovery.com.
Krystina Jones
krystina.jones@kldiscovery.com
Home / News & Events / Press Releases
© KLDiscovery. All rights reserved.


We had so much fun at the opening night VIP Experience at Disney On Ice presents Reach for the Stars. This has to be my favorite so far. It was such a great show.
The boys got to meet Mickey and give him a hug. They played and had sword fights and ran off the sugar that they ate. And they got this awesome swag bag with Flounder.
Disney On Ice Presents Reach for the Stars is in town from March 28 – April 8, at Sunrise BB&T Center and Miami AmericanAirlines Arena. We followed our dreams watching this adventure-filled show including beloved characters from Tangled, The Little Mermaid, Beauty and the Beast and Frozen. I have a soft spot for Olaf in Frozen. He's one of my favorites.
There was so much to see from our favorite characters like Rapunzel. We got tangled up with a chorus of harmless hooligans when they got a visit from the spirited Rapunzel and her charming ally, Flynn Rider, on their journey to see the floating lights. I LOVED the floating lights, so pretty.
We sang "Let it Go" like we always do! It's so much fun to hear the audience chime in too.
This is definitely a show worth seeing! We came home so thrilled.
So, BE OUR GUEST, get tickets and enjoy the show! My readers Save $5 on tickets when you use code KIDSAVE18 online at www.disneyonice.com.
This looks like so much fun! I know that my kids would absolutely love going to one of these shows. 🙂 Thanks for sharing your experience!
That sure would have been fun to see. Looks quite enjoyable.
Disney always has fantasies and smiles for little children and "big children" everywhere!! We have always had a great time at the Disney on Ice Shows! Great talent and shows! I get excited still when I know we're going to do or see something Disney! I really liked the videos you shared- Thank you! I have never asked for a refund from any Disney's entertainment! I hope Disney's mindset NEVER changes!!


text:
15 years of Daisy Chain - Colin Laver
Colin Laver and his wife Helen made the first ever donation to Daisy Chain – "It was the grand sum of £2 to open a bank account," he chuckles.
It came about as the couple were having dinner with Lesley and her husband Duane. Colin says, "Lesley told us all about her dream of a haven for children with autism. At that time, she went to a crèche with Jacob but said she felt uncomfortable because her child was different. She wanted somewhere she could go and feel comfortable and felt that if she needed that then surely there were other parents who did too.
"Lesley was so passionate about starting a support group believing there were lots of other parents in the same situation who needed to talk and needed somewhere to let their children have some freedom without feeling uncomfortable. Lesley was really excited about the idea and was asking for ideas on what she should do next. I can't remember why but for some reason there was £2 on the table and Helen pushed it across to her and said 'open a bank account' and that was the start," Colin smiles.
"When she got Calf Fallow Farm, I would pop in and help out. Of course, we were devastated when Lesley died, it was so unexpected. There was a real sense of needing to make this dream live for Lesley."
Colin was then a full-time teacher so his involvement was occasional volunteering, "Seeing Daisy Chain develop and grow was amazing," he recalls. Then five years ago when he retired from teaching, Colin volunteered with Daisy Chain. His background in teaching and bringing children with special needs to the farm from his school Rosebrook Primary in Stockton, meant Colin was ideally placed to work one-to-one with students.
"I also did some travel training with students, using public transport and practising how to get from A to B independently. It was important for the students to have skills to get places by themselves."
Colin's final role was working in the crèche at Daisy Chain before he chose to retire at 65. "I have loved being at Daisy Chain, to see it grow from that first £2 to a million-pound purpose-built day centre, the barn and the farm. But what really makes Daisy Chain special is the people, their dedication is incredible and it is more than just a job for the staff."
Despite becoming a teacher, Colin admits he has real empathy with what the charity does. "I struggled myself at school. My first day at primary school I was caned seven times because I couldn't sit still or stop talking because I was so excited. I was also afraid of the dark and noise, I hated having to go to a railway station because it was so noisy." Colin left school without any qualifications and later discovered he had mild dyslexia, "It was sport that saw me through," he admits.
Now Colin hopes Daisy Chain will continue to go from strength to strength, "When you look out over the fields and the site you can see the future potential of what the charity can offer. It has grown so much and there are some amazing people offering some really wonderful support for families.
"It's been fantastic to see everything that has been done over the years to fulfil Lesley's dream. She would have loved it."
Published: 8th May, 2018
15 years of Daisy Chain - Leah Hanson
"Walking through that main entrance and seeing what Daisy Chain is now makes me so proud. I am truly impressed with what Daisy Chain has become and the amount of support it provides to families..."
15 years of Daisy Chain - Cummins
As a global company, Cummins is committed to giving back to the communities it operates in – and in the Tees Valley area, Daisy Chain has been a major beneficiary of this pledge ...
15 years of Daisy Chain - Paul Good
"Where Daisy Chain is now, 15 years later, is almost unbelievable – it's gone from a group of friends trying to make it happen to a major source of support for 2,000 families affected by autism in the Tees Valley..."
15 years of Daisy Chain - Andrew and Julie Barnett
"It's fantastic how much it has grown and the support it offers. It is everything Lesley dreamed of..."
15 years of Daisy Chain - PD Ports
"It's great to see Daisy Chain celebrating 15 years this year and we look forward to our continued involvement in its development..."
15 Years of Daisy Chain - Sheila and Amy Buttery
"Daisy Chain has had a place in our hearts for all of its fifteen years and it will continue to - we all love it."
15 years of Daisy Chain - Mandy and Charlotte
Mandy and Charlotte were one of the first families to visit Daisy Chain and 15 years on they're still attending ...
15 years of Daisy Chain - Craig Harvey
In Daisy Chain's fifteenth anniversary year, Craig Harvey will be completing his fifteenth Great North Run for the autism charity based in Norton...
15 years of Daisy Chain - Bruce Merrick
"Daisy Chain is a family charity, both for families and like a family to all those involved with it..."
15 years of Daisy Chain - Ian Sanderson
When a couple of clients seeking financial advice from Ian Sanderson told them their story and involvement with Daisy Chain, Ian was sold...


Australia's Great Barrier Reef Marine Park Authority (GBRMPA) on Friday approved the dumping of up to three million cubic metres of dredge material within the park's boundaries.
The decision follows the government giving the green light to a major coal port expansion for India's Adani Group on the reef coast in December, under some of the strictest-ever environmental conditions.
The plan will see Adani dredge some three million cubic metres from the seabed to allow for freighters to dock at the port in Abbot Point, lifting the facility's capacity by 70 percent to make it one of the world's largest coal ports.
Conservationists have warned it could hasten the demise of the reef, which is already considered to be in "poor" health, with dredging smothering corals and seagrasses and exposing them to poisons and elevated nutrients.
The reef is already facing pressures from climate change, land-based pollution and crown of thorns starfish outbreaks.
GBRMPA chairman Russell Reichelt said he recognised there was intense community concern and debate about the application by North Queensland Bulk Ports Corporation to dispose of dredge spoil in the park.
But he said allowing the project to proceed would help contain development to existing ports, and the reef itself and seagrass meadows would still be protected. "This approval is in line with the agency's view that port development along the Great Barrier Reef coastline should be limited to existing ports," he said. "It's important to note the sea floor of the approved disposal area consists of sand, silt and clay and does not contain coral reefs or seagrass beds."
The GBRMPA, whose board is currently under investigation for its links to the mining industry, added that the strict environmental conditions imposed on the project by the federal government would help protect the reef.
WWF Australia has said the material dredged during the port expansion would be enough to fill 150 000 dump trucks that "lined up bumper-to-bumper would stretch from Brisbane to Melbourne", a distance of more than 1 000 km.
I'm a 29 year old woman looking to meet men between the ages of 25 and 80.


text:
Family Camps & Retreats
Tip: Using Maps On Camp Channel
While searching or browsing the Camp Channel's directory of summer camps, you may come across various maps displayed which are associated with a set of search results or a particular page such as a U.S. State or Canadian Province. You may also notice small colored markers positioned over various locations on such maps. These markers have numbers which correspond to the listing results displayed below the map and allow you to visually discern the locations of some of the camps listed on that page. Click on the link below for an example:
Summer Camps In California
On the California state map displayed on the page above, if you click on any of the numbered markers you will notice a small popup window which contains summary information about the corresponding camp listing to the numbered result which appears in the list of all camps in California. Within the small popup window you may also see multi-media elements such as photo thumbnail images which appear alongside the summary information. Also within the small popup window, there is always a link to the listing's full record titled "Click Here To View This Camp's Complete Listing". By clicking on this link you will be able to view the full record for that particular camp listing.
Please note that not all listings have markers which appear on any given map and that marker numbers corresponding to particular listings will change from page to page and even from search to search. Moreover, not all searches or pages have corresponding maps.
For those camp listings which do reflect a map location, you can access an individual map of their particular location directly from the search results by clicking on the small link titled "Map" directly under the button titled "More info" on the far right of all search results. Likewise, if you're in the midst of viewing the full listing for any given camp, you can also access an individual map (if present) of their particular location by clicking on the link titled "View Map" which appears on the right hand side of the aqua/blue bar at the top of the listing. Similar to viewing a camp's individual map directly from the search results, this will invoke a small popup window reflecting the camp's location; however, since there is only a single location denoted, the marker does not have a number in this case.
Summer Camps and Early Bird Enrollment Rates
While it might be sad news to some that Punxsutawney Phil saw his shadow and winter weather might not release it's grip for some time, it's never too early to start planning for summer camp. In fact, making firm arrangements at this time of the year might translate into a bit of a savings on your child's summer enrollment fees in the form of what's often referred to as an "Early Bird Discount".
Many summer camps will offer parents the opportunity to either submit a deposit or payment in full in the months prior to camp in exchange for a lower rate. Typically, there is a "cut off" date or deadline which separates early bird and standard regular season rates. The existence and details of early bird discounts varies from camp to camp, so it's important to contact your camp director to learn whether such a program exists and if so what are the specific requirements and other details.
Camp Resources & News
News & Feature Updates (24)
Summer Camp Resources (32)
Search Resources & News


text:
« Patent Granted for RNA Transcription Technology
Drug Pricing Reform Even Big Pharma Might Like »
Lung Function App Service Expanded to Any Phone
By Alan, on May 3rd, 2016
SpiroCall provides spirometry tests with early cell phones and landlines. (University of Washington)
3 May 2016. A computer science lab extended the abilities of its smartphone app that measures lung function to a call-in service for any phone in the world. The team led by engineering and computer science professor Shwetak Patel at University of Washington will discuss the new service at the ACM Computer-Human Interaction (CHI) 2016 conference that begins on 7 May in San Jose, California.
Patel's UbiComp lab in Seattle developed in 2012 a smartphone app known as SpiroSmart that measures the flow rate and volume of lungs when inhaling and exhaling, functions usually tested with a spinometry instrument in a clinic and some home devices. Spinometers are used to diagnose lung diseases, such as asthma and chronic obstructive pulmonary disease, or COPD, as well as monitor lung functions over time in people with these disorders.
As reported in Science & Enterprise, Patel's team built the SpiroSmart app to capture sound waves from a person blowing into the smartphone's microphone. The app uploads the recorded sound file to a server, where a model of a human trachea and vocal tract is used to analyze the sound waves. Software on the server then detects breathing irregularities, with a report sent back to the app. Since 2012, Patel and colleagues tested SpiroSmart with more than 4,000 individuals, and clinical trials of the app are underway in the U.S., India, and Bangladesh.
While the SpiroSmart app makes it possible to expand spirometry to more people than before, the smartphone requirement still leaves out many individuals in low-resource regions or those without smartphones. To fill those gaps, the lab devised a call-in service known as SpiroCall that allows individuals to measure their lung functioning with regular voice telephone lines and early cell phone models. Reports are then sent back as text messages to phones on cellular networks.
SpiroCall had to overcome lower audio quality when a person breaths into a telephone handset or cell phone, then carried over voice telephone line or cellular frequency. To meet this challenge, the UbiComp team of Patel and doctoral students Mayank Goel and Elliot Saba rewrote its analytical algorithms, first breaking down the breathing flow rate signals, then calculating the regression lines into a single median estimate of lung functioning.
The researchers also encountered wide variation in types of telephones and the distance between the caller's mouth and handset that influenced audio quality. In addition, people with severe lung problems could not generate breathing sounds loud enough to be captured consistently by the call-in system. To overcome these problems, the team designed a simple plastic whistle, which they produced on a 3-D printer, modeled after a similar whistle created in 1954 that changes pitch when breathing flow rates change.
Patel and colleagues recruited 50 volunteers to test SpiroCall, of which 16 had asthma or other lung conditions. The test recorded and analyzed lung functions with voice telephone calls on smartphones, earlier-model cellphones, and landline handsets. The calls were captured on voicemail, then uploaded to the SpiroCall server. The volunteers also tested the system with and without the plastic whistle, and took measurements of their lung functions with clinical spirometers.
The results show lung function measurements made with SpiroCall, both with and without the plastic whistle, varied on average 6.2 percent from clinical spirometers, within standard margins of error for those devices. Using the whistle, however, reduced the number of false positive readings and made the estimation models easier to generalize across different types of phones.
In the following video, Goel and Saba tell more about SpiroCall.
Phones, Wearables Studied to Monitor Brain Disorders
Medical Google Glass Start-Up Raises $17M in Venture Funds
Smartphone-Based Sensor Gives Early Epilepsy Warning
$500K Challenge Seeks Mood Research Ideas with iPhone
Wide Variation Found in Consumer Blood Tests
New products biomedical, computer science, engineering, life sciences, mathematics, medical device, physical sciences, software, university


This Instructable is the first in a series documenting the construction of a DIY 3 axis CNC router.
I supplied my own materials and provided the sweat equity to build my parts from aluminum bar stock. during the process I learned quite a bit about machining and taught the students more about CNC Router tables.
I wanted to make the X axis easier to adjust and keep in aligned to the angle iron guide rails. I also wanted to make the X axis extrusion less prone to flexing. On the X axis carriage I widened the bearing mount rods and eliminated the threaded rods in favor of a shaft and spacer bushing.
The new Aluminum CNC Router build has one other benefit I was not counting on. It is able to lift significantly more weight on the Z axis. I have plans for an MDF version available but have not decided if I should make plans for the aluminum available. This is also my entry for the Universal Laser Cutter Contest.The goal of this Instructable is not to show a full step by step progression but rather to pass along my experiences with making my own CNC.
I am constantly modifying my 3 axis CNC Router table to add new features and functionality.
I turned the spacer bushings on a metal lathe to ensure a tight fit. I also added an adjustable bottom bearing system with set screws to lock the carriage in place. The major Z axis change from the first version is to do away with the lead screw in favor of a Rack & Pinion system. This step shows the progression of the Z axis - this was the most complex and time consuming assembly to manufacture. I have slowly been tweaking the machines construction for the last 4 years to the point that it is now a distant cousin to the original 3 Axis CNC Router with MDF carriages and Lead screws. I spent a good deal of time on that modification (The Warp Drive Project) and even made plans available. I designed this machine for the sculpture department to primarily cut soft material (foam, wax, some plastic and wood).
Each upgrade has worked better than the previous version so I decided make an aluminum CNC router build.
I was fortunate to have the chance to work along side the Mechanical Engineering Technology students at Morrisville State College and help the students make A CNC Router table.
I have yet to see any flexing on the machine we built at the college (which uses the same 8020 mounting scheme. There is a smooth surface for the CNCRP drives to rotate on and a threaded stud for the lock nut.
Besides that, I got a great deal of pleasure from experimenting and building things in a new way.
I choose these plans a jumping off point - extracting what I needed and adding to the design to fit my needs. I really like the dual lead screw design - it has given us a lot of flexibility to have a movable table underneath the machine. Linear motion control, next to the drive train, is often the most expensive system on a CNC device and the Solsylva plans present a simple yet elegant solution to cutting the cost of linear movement buy using roller skate bearings, angle iron, and EMT conduit.
Pages of commentary on construction, and extended, because they make the straightest most essential elements of woodworking.
Traditional English bodger's shaving horse and available in left- and right-hand models.
Huge 45" (you can drill in the middle of a 45.
Agency Furniture and role Equipment article and Teron Baker carry a completed table away.